Before you sell to, join or invest in NLS Pharmaceutics Ltd.
MentionFox check on NLS Pharmaceutics Ltd.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/nls-pharmaceutics-ltd-form-d-25000002
Check NLS Pharmaceutics Ltd. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about NLS Pharmaceutics Ltd.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
NLS Pharmaceutics Ltd. filed a Form D with the Securities and Exchange Commission on 2025-04-14.
NLS Pharmaceutics Ltd. filed a Form D notice of an exempt securities offering with the SEC on April 14, 2025. The filing reports $2M sold. Its industry group is Pharmaceuticals. It names Alexander Zwyer (Chief Executive Officer), Ronald Hafner (Chairman of the Board of Directors), Nicole Fernandez-McGovern (Chief Financial Officer and Chief Operating Officer) (SEC Form D, April 14, 2025).
Is this your company?
Sell to companies like NLS Pharmaceutics Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-04-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns NLS Pharmaceutics Ltd.
Free to see. No signup.
More on the people and the money behind NLS Pharmaceutics Ltd., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when NLS Pharmaceutics Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when NLS Pharmaceutics Ltd. raises, hires or launches. No email unless you switch it on.
Watch NLS Pharmaceutics Ltd. →Get the full cited report on NLS Pharmaceutics Ltd.
What the filing shows about NLS Pharmaceutics Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NLS Pharmaceutics Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives NLS Pharmaceutics Ltd.'s address as The Circle 6, Zurich, V8 8058.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for NewcelX Ltd. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
NLS Pharmaceutics Ltd. is a registered filer with the SEC (CIK 1783036) and has filed since 2022-10-14. 10 filings are on record, the latest on 2026-08-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
NLS Pharmaceutics Ltd.'s Form D of 2025-04-14 names Alexander Zwyer, Ronald Hafner, Nicole Fernandez-McGovern and 4 more as its officers, directors or promoters.
Its new offerings report $33.61M sold across 10 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
On the filing as: Executive Officer, Director.
Alexander Zwyer is named as Chief Executive Officer on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
On the filing as: Director.
Ronald Hafner is named as Chairman of the Board of Directors on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
On the filing as: Executive Officer.
Nicole Fernandez-McGovern is named as Chief Financial Officer and Chief Operating Officer on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
Florence Allouche Aknin is named as Director on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
Gian-Marco Rinaldi de la Cruz is named as Director on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
Audrey Greenberg is named as Director on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
Olivier Samuel is named as Director on the Form D that NLS Pharmaceutics Ltd. filed with the SEC on 14 April 2025, one of 7 people that filing names.
7 people named on the filing — 2 holding an executive role and 5 as directors only.
Named as of the 2025-04-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about NLS Pharmaceutics Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NLS Pharmaceutics Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NLS Pharmaceutics Ltd. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NLS Pharmaceutics Ltd.You get an alert in MentionFox the next time this company shows up.
If you're behind NLS Pharmaceutics Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for NLS Pharmaceutics Ltd.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/nls-pharmaceutics-ltd-form-d-25000002